Skip Navigation LinksSkip Navigation Links
Centers for Disease Control and Prevention
Safer Healthier People
Blue White
Blue White
bottom curve
CDC Home Search Health Topics A-Z spacer spacer
spacer
Blue curve MMWR spacer
spacer
spacer

The content on this page is being archived for historic and reference purposes only. The content, links, and pdfs are no longer maintained and might be outdated.

Notice to Readers U.S.-Manufactured Pentamidine Isethionate Cleared for Investigational Use

A U.S.-manufactured preparation of pentamidine isethionate has undergone satisfactory completion of chemical and biologic tests, and CDC is now able to include this preparation in its claimed investigational exemption for a new drug for treatment of Pneumocystis carinii pneumonia. The Investigational New Drug status for the U.S.-manufactured preparation makes it unnecessary for CDC to distribute the foreign-produced product (pentamidine methanesulfonate) described in the May 4, 1984, issue of the MMWR (33:225-6). The U.S. preparation is being synthesized by Aldrich Chemical Company, Milwaukee, Wisconsin, and packaged for pharmaceutical use by LyphoMed, Inc., Melrose Park, Illinois.

There are two minor differences between the LyphoMed-manufactured product and the previously used May & Baker preparation of pentamidine isethionate. First, the LyphoMed product contains more pentamidine per vial than the May & Baker product (300 mg, compared with 200 mg). Second, the two preparations differ in their physical appearance. May & Baker uses a "dry fill" manufacturing process that leaves a fluffy white powder in the vial, whereas LyphoMed uses a "wet fill" process, followed by lyophilization, leaving a dry "plug" of white powder at the bottom of the vial.

The dosage of the LyphoMed product is the same as for the May & Baker product (4 mg (salt)/kg body weight). Reported by Div of Parasitic Diseases, Div of Host Factors, Center for Infectious Diseases, CDC.

Disclaimer   All MMWR HTML documents published before January 1993 are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.

**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.

Page converted: 08/05/98

HOME  |  ABOUT MMWR  |  MMWR SEARCH  |  DOWNLOADS  |  RSSCONTACT
POLICY  |  DISCLAIMER  |  ACCESSIBILITY

Safer, Healthier People

Morbidity and Mortality Weekly Report
Centers for Disease Control and Prevention
1600 Clifton Rd, MailStop E-90, Atlanta, GA 30333, U.S.A

USA.GovDHHS

Department of Health
and Human Services

This page last reviewed 5/2/01